Evidence map›Paper›PMID 40625468›Full record

ArticleCureus2025

Minimal Change Disease in a Young Adult With Neurofibromatosis Type 1.

Patricia B Clissa, Cecilia Maria Lima da Costa, Sabri S Sanabani

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Patricia B ClissaImmunopathology Laboratory, Butantan Institute, São Paulo, BRA.
Cecilia Maria Lima da CostaPediatric Oncology, A.C.Camargo Cancer Center, São Paulo, BRA.
Sabri S SanabaniLaboratory of Medical Investigation LIM03, Clinics Hospital, Faculty of Medicine, University of São Paulo, São Paulo, BRA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterized by café-au-lait macules, neurofibromas, and a predisposition to various tumors. While the disease is primarily associated with neural and dermatologic manifestations, renal involvement is extremely rare. We present the case of a 20-year-old woman with NF1 who developed steroid-sensitive minimal change disease (MCD) confirmed by renal biopsy. MRI findings revealed plexiform neurofibromas involving the cervical nerve roots and the right temporal region. The patient was started on prednisolone 40 mg/day, achieving remission with normalized proteinuria, but relapsed with edema and proteinuria (7.74 g/L) during tapering. Prednisone was re-initiated at 30 mg/day, tapered to 2.5 mg every other day, and she remains in clinical and biochemical remission while continuing this low dose, with plans to discontinue after one month if remission persists. As researchers, the authors aim to report this rare association to advance scientific understanding of NF1-related renal pathology. This case underscores the importance of considering renal pathology in NF1 patients with nephrotic syndrome and raises the possibility of a biologically plausible link between NF1-related dysregulation of the Ras signaling pathway and podocyte injury as observed in MCD.

Indexed as

corticosteroidsminimal change disease (mcd)neurofibromatosis type 1 (nf1)podocyte injuryproteinuria

Identifiers

PMID40625468
PMCPMC12229825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.